Catalog No.
Product Name
Application
Product Information
Citations
-
Her3 PROTAC Degrader
PROTAC Her3 Degrader-8 is a potent Her3 PROTAC degrader that facilitates the ubiquitination and subsequent degradation of the Her3 protein. This compound is particularly relevant for studies focused on lung adenocarcinoma and ovarian cancer, enabling researchers to investigate the role of Her3 in these malignancies. The design incorporates a specific Her3 ligand, an E3 ligase ligand, and a linker, which optimizes its efficacy as a targeted degradation tool in research applications. -
EGFR PROTAC Degrader
SJF-1528 is a potent EGFR PROTAC degrader that selectively targets wild-type EGFR and Exon 20 Ins mutant EGFR, exhibiting DC50 values of 39.2 nM and 736.2 nM, respectively, in OVCAR8 and HeLa cells. This compound facilitates the ubiquitination and subsequent degradation of EGFR and also affects HER2 levels. SJF-1528 is valuable for breast cancer research, providing insights into targeted degradation mechanisms and alterations in growth factor signaling pathways. -
PARP PROTAC Degrader
PROTAC PARP1 degrader-2 is a targeted protein degradation compound designed to specifically degrade PARP1. With a DC50 of less than 10 nM in MDA-MB-231 cells, it demonstrates potent efficacy in inducing degradation. Additionally, this compound inhibits cell viability in MDA-MB-436 cells with an IC50 of less than 100 nM, making it a valuable tool for research in cancer therapeutics and the mechanistic study of PARP1 function. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-44 is a selective degrader targeting the EZH2-PRC2 complex through the recruitment of the CRBN E3 ligase, facilitating proteasome-mediated degradation of EZH2, SUZ12, and EED. This process leads to a marked reduction in H3K27me3 and CARM1 levels, resulting in potent antiproliferative effects. It induces mitochondrial dysfunction and promotes apoptosis by modulating Bcl-2 family proteins, demonstrating minimal cytotoxicity in normal human mammary epithelial, liver, and kidney cells. PROTAC EZH2 Degrader-44 serves as an effective research tool for investigating targeted therapies in triple-negative breast cancer. -
PARP14 PROTAC Degrader
RBN012811 is a selective PROTAC degrader that targets PARP14, facilitating its degradation through a ternary complex with cereblon by binding at the NAD+ site. With an IC50 of 10 nM, RBN012811 efficiently reduces endogenous PARP14 levels in various cell lines and primary human macrophages. This reduction is associated with decreased IL-10 production and IFN-β mRNA, alongside an increase in phosphorylated STAT1, thereby enhancing inflammatory signaling and inhibiting interferon-induced ADPr condensate formation. RBN012811 also influences viral replication dynamics, promoting HSV1 replication while diminishing VSV replication, making it valuable for research in cancer biology and viral infections. -
KAT2A/KAT2B PROTAC Degrader
PROTAC KAT2A/B degrader-1 is a targeted degrader that selectively induces the degradation of histone acetyltransferases KAT2A and KAT2B. This compound demonstrates significant inhibition of proliferation in acute myeloid leukemia and small cell lung cancer cells. PROTAC KAT2A/B degrader-1 is a valuable tool for studying the roles of KAT2A and KAT2B in cancer biology and may facilitate the development of novel therapeutic strategies for these malignancies. -
Molecular Glue
MNN-02-155 is a bivalent molecular glue that binds simultaneously to p300/CBP and BCL6. This compound effectively activates the BCL6-target reporter gene, leading to significant induction of cell death. MNN-02-155 is particularly relevant for research into diffuse large B cell lymphomas (DLBCLs), providing insights into potential therapeutic strategies involving BCL6 modulation. -
Ligands for Target Protein for PROTAC
CBP/p300 ligand 10 is a selective ligand for the CBP/p300 proteins, facilitating their targeted degradation. This compound serves as a valuable component for the development of PROTACs, specifically enabling the synthesis of CBP/p300 Degrader-2. Its utility in research applications includes studies focused on cellular signaling pathways and potential therapeutic interventions in diseases associated with dysregulated CBP/p300 activity. -
ZBTB7A/WIZ Dual Molecular Glue Degrader
BMS-986470 is a dual molecular glue degrader that targets ZBTB7A and WIZ through modulation of the CRBN E3 ligase. This compound demonstrates potent induction of γ-globin, making it a valuable tool for studying hemoglobin disorders. BMS-986470 holds significant potential for research applications related to sickle cell disease (SCD), facilitating investigations into therapeutic strategies and molecular mechanisms underlying the condition. -
Molecular Glue
TCIP3 is a bivalent molecular glue that targets p300/CBP and BCL6. By redirecting p300 and CBP, TCIP3 activates programmed cell death genes that are typically suppressed by the oncogenic driver BCL6, making it a valuable tool for investigating diffuse large B cell lymphomas (DLBCLs). Importantly, TCIP3 demonstrates no toxicity to non-transformed tonsillar lymphocytes or fibroblasts, ensuring the safety of experimental applications. -
WIZ Molecular Glue
WIZ degrader 8 is a selective degrader targeting the transcription factor WIZ, promoting the degradation of WIZ and subsequently inducing the expression of fetal hemoglobin (HbF). This compound has significant potential for research applications related to sickle cell disease, as it may serve as a therapeutic strategy to modulate HbF levels and alleviate disease symptoms. -
p300 PROTAC Degrader
BT-O2C is a selective p300 PROTAC degrader that effectively reduces p300 levels in HAP1 cells. It exhibits significant cytotoxicity in CIC:DUX4 sarcoma cell lines, with IC50 values ranging from 152 to 221 nM, and notably decreases the expression of target genes associated with CDS, such as ETV1, ETV4, and ETV5. This compound serves as a valuable tool for research in cancer biology, facilitating studies on p300's role in oncogenic processes. -
PCAF/GCN5 PROTAC Degrader
GSK699 is a PROTAC degrader targeting PCAF/GCN5, promoting their ubiquitination and subsequent proteasomal degradation. This compound effectively inhibits the production of key cytokines and chemokines, such as interleukin-6 (IL-6) and CXCL1/GROα, thus demonstrating significant anti-inflammatory properties. GSK699 is suitable for investigations related to inflammatory diseases and other conditions modulated by these target proteins. -
BRD4/CBP/p300 PROTAC Degrader
PROTAC CBP/p300/BRD4 Degrader-1 is a dual-target PROTAC degrader that specifically targets BRD4, CBP, and p300, achieving DC50 values of 8.8 pM, 6.55 nM, and 1.05 nM, respectively. This compound promotes CRBN- and proteasome-mediated degradation of BRD4 and CBP/p300, leading to the downregulation of c-Myc and acetyl-H3K27, and inducing apoptosis. It exhibits significant antiproliferative and antitumor effects, demonstrated by tumor growth inhibition in xenograft models. PROTAC CBP/p300/BRD4 Degrader-1 is a valuable tool for research focused on prostate and colorectal cancer. -
HDAC PROTAC Inhibitor
JPS016 is a class I histone deacetylase (HDAC) PROTAC inhibitor that targets HDAC1, HDAC2, and HDAC3 for ubiquitination and proteasomal degradation via VHL E3 ligase recruitment. This compound demonstrates significant anticancer activity by reducing the viability of colon cancer cells and inducing apoptosis. Additionally, JPS016 activates the PINK1/Parkin-mediated mitochondrial autophagy pathway, enhancing cardiomyocyte viability, alleviating mitochondrial damage, and decreasing mitochondrial ROS production. It is valuable for research into colon cancer and sepsis-related cardiac dysfunction. -
PROTAC HDAC6 Degrader
HDAC6 Degrader-3 is a selective inhibitor that promotes the degradation of histone deacetylase 6 (HDAC6) through ternary complex formation and the ubiquitin-proteasome pathway, exhibiting a DC50 value of 19.4 nM. With IC50 values of 4.54 nM for HDAC6 and 0.647 μM for HDAC1, it effectively induces significant hyperacetylation of α-tubulin. This compound is valuable for research applications focused on neurodegenerative diseases and cancer, where modulation of HDAC6 activity may play a critical role. -
PROTAC HDAC Degrader
HD-TAC7 is a highly effective PROTAC HDAC degrader, specifically targeting histone deacetylases HDAC1, HDAC2, and HDAC3 with IC50 values of 3.6 μM, 4.2 μM, and 1.1 μM, respectively. This compound has demonstrated the ability to reduce NF-κB p65 levels in RAW 264.7 macrophages. HD-TAC7 is suitable for research applications focused on inflammatory diseases, including asthma and chronic obstructive pulmonary disease (COPD). -
PROTAC HDAC Degrader
JPS036 is a benzamide-based HDAC degrader that operates through the Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC) mechanism. This compound selectively degrades class I histone deacetylases (HDAC1 and HDAC2), demonstrating significant biological activity by promoting the expression of differentially expressed genes and enhancing apoptosis in HCT116 cells. JPS036 serves as a valuable research tool for studying the roles of HDACs in cellular processes and disease models. -
EZH2 Degrader
PROTAC EZH2 Degrader-3 (compound ZJ-20) specifically targets and degrades the EZH2 protein through a proteolysis-targeting chimera (PROTAC) mechanism. This compound demonstrates potent inhibition of EZH2 expression as well as a significant reduction in other PRC2 subunits and H3K27me3 levels. Additionally, PROTAC EZH2 Degrader-3 exhibits anti-proliferative effects, inducing cell cycle arrest in the G0-G1 phase and promoting apoptosis in cancer cells, making it valuable for research in cancer therapeutics and epigenetic regulation. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-9 is an orally active PROTAC that selectively degrades EZH2 via the ubiquitin-proteasome pathway. By downregulating PRC2 core subunits and inhibiting H3K27me3, it effectively reverses PRC2-mediated gene silencing and disrupts EZH2 non-catalytic target gene activation. PROTAC EZH2 Degrader-9 demonstrates potent antiproliferative effects on various cancer cell lines, inducing cell cycle arrest and apoptosis. This reagent is valuable for research focused on leukemia, lymphoma, and non-small cell lung cancer. -
CARM1 PROTAC Degrader
CARM1 degrader-1 is a selective PROTAC degrader targeting CARM1, exhibiting a DC50 value of 8.1 nM. It effectively degrades CARM1 through a VHL- and proteasome-mediated mechanism, leading to a reduction in the methylation levels of CARM1 substrates in various cell-based assays. Additionally, CARM1 degrader-1 demonstrates the ability to inhibit cancer cell migration, making it a valuable tool for investigating mechanisms in breast cancer research. -
Ligands for Target Protein for PROTAC
Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH is a ligand specifically designed for EZH2, functioning as a key component in PROTAC technology by recruiting E3 ligases. This compound demonstrates potential biological activity in targeted protein degradation, particularly in the context of lymphoma research. Its unique structure allows for the exploration of novel therapeutic strategies aimed at modulating EZH2 activity and its downstream effects in cancer biology. -
PROTAC Linker
MAK683-CH2CH2COOH is a PROTAC linker that specifically binds to embryonic ectoderm development protein (EED). This compound is instrumental in facilitating targeted protein degradation when paired with a VHL ligand for E3 ubiquitin ligase. Research applications include the development of PROTAC EED degrader-1 and PROTAC EED degrader-2, making it a valuable tool for studying EED-related pathways and therapeutic interventions. -
PROTAC Glutathione Peroxidase Degrader
NC-R17 is a non-covalent degrader targeting Glutathione Peroxidase 4 (GPX4) through the PROTAC mechanism, designed to induce ferroptosis in cancer cells. Exhibiting significant antitumor activity, NC-R17 facilitates the targeted degradation of GPX4, contributing to research in cancer biology and therapeutic strategies. The compound combines a Demethyl-RSL3 ligand for GPX4 with an E3 ubiquitin ligase ligand derived from Lenalidomide, connected by a specific PROTAC linker to enhance its biological activity. -
GPX4 PROTAC Degrader
PROTAC GPX4 degrader-4 selectively targets GPX4, functioning as a PROTAC degrader with a DC50 of 5.32 nM. This compound effectively inhibits the proliferation of RT4, T24, and J82 bladder cancer cell lines, exhibiting IC50 values of 0.09, 2.97, and 7.58 μM, respectively. PROTAC GPX4 degrader-4 promotes the accumulation of lipid reactive oxygen species (ROS) and triggers ferroptosis in T24 and RT4 cells. Additionally, it demonstrates significant antitumor efficacy in a T24 tumor-bearing BALB/c nude mouse model, making it a valuable tool for bladder cancer research. -
Molecular Glues
Lenalidomide hemihydrate functions as a molecular glue through its activity as an immunomodulator. This compound selectively binds to the ubiquitin E3 ligase cereblon (CRBN), leading to the ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 complex. Lenalidomide hemihydrate is effective in inhibiting the proliferation of mature B-cell lymphomas, including multiple myeloma, and promotes the release of IL-2 from T cells, making it a valuable tool in cancer research. -
SKP2 Molecular Glue Degrader
XMU-MP-8 is a potent molecular glue degrader that targets the oncoprotein SKP2. It binds to the F-box domain of SKP2 and the N-terminal TPR domain of the E3 ligase STUB1, facilitating the formation of a stable SKP2-SKPer1-STUB1 ternary complex. This interaction leads to SKP2 ubiquitination and subsequent proteasomal degradation, selectively eliminating SKP2-expressing cancer cells. XMU-MP-8 demonstrates significant tumor suppression and favorable safety profiles in vivo, making it a valuable tool for cancer research, particularly in studies related to non-small cell lung adenocarcinoma (NSCLC) and prostatic adenocarcinoma. -
TRIM21 Molecular Glue
HGC652 is a molecular glue degrader that specifically targets TRIM21, facilitating the disruption of nuclear membrane integrity through a TRIM21-dependent mechanism. By binding with high affinity to the PRY-SPRY domain of TRIM21, HGC652 promotes the interaction between TRIM21 and NUP98, enhancing E3 ligase activity. This results in the polyubiquitination and subsequent proteasomal degradation of nucleoporins such as NUP155 and GLE1, leading to altered nuclear morphology, enhanced genomic instability, and ultimately, cancer cell death. HGC652 serves as a valuable tool for investigating nuclear envelope dynamics and the role of TRIM21 in cancer research. -
Molecular Glue
CC-647 is a molecular glue modulator that targets the Cereblon (CRBN) E3 ubiquitin ligase. It enhances the interaction between CRBN and ZBTB16, along with its oncogenic fusion protein RARα-ZBTB16, with a DC50 of 103 nM. CC-647 is particularly valuable for the investigation of ZBTB16-RARα-associated acute promyelocytic leukemia (APL) and offers potential insights into therapeutic strategies for this malignancy. -
E3 Ligase Ligand
E3 Ligase Ligand 36 is a potent E3 ligase ligand that serves as a key substrate for the synthesis of proteolysis-targeting chimeras (PROTACs). It facilitates targeted protein degradation and has been utilized in the development of PROTAC BRM/BRG1 degrader-1. This compound provides valuable tools for research in protein regulation and therapeutic applications in various diseases. -
Molecular Glues
MG Degrader 3 is a molecular glue that targets the CRBN protein, inducing targeted protein degradation. It exhibits potent anti-proliferative activity in multiple myeloma cell line MM.1S, with an IC50 of 8.7 nM. This compound is valuable for studies investigating protein degradation mechanisms and therapeutic approaches in cancer research. -
E3 Ligase Ligand-Linker Conjugate
Ethanolamine-Thalidomide-4-OH is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation via the proteolysis targeting chimera (PROTAC) approach. This compound combines a cereblon (CRBN) ligand with a linker, enabling the synthesis of various PROTACs, such as PROTAC BTK Degrader-13. It serves as a crucial tool for researchers investigating selective protein degradation mechanisms and developing novel therapeutic strategies. -
PROTAC Linker
Azido-PEG2-C2-amine is a PEG-based linker designed for use in PROTAC synthesis. This compound features an azide moiety that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted azide-alkyne cycloaddition (SPAAC) reactions, facilitating conjugation with alkyne-bearing molecules. Additionally, Azido-PEG2-C2-amine serves as a non-cleavable linker for the development of antibody-drug conjugates (ADCs), making it a versatile tool in chemical biology and drug discovery applications. -
ADC/PROTAC Linker
DBCO-PEG5-NHS ester is a cleavable linker designed for use in antibody-drug conjugates (ADCs) and PROTAC synthesis. This PEG/alkyl/ether-based reagent facilitates the formation of stable covalent bonds through strain-promoted alkyne-azide cycloaddition (SPAAC), targeting azide-functionalized molecules. Its defined structure enhances the efficacy and specificity of therapeutic compounds, making it a valuable tool for researchers in the development of targeted therapies. -
PROTAC Linkers
Bromo-PEG2-C2-azide is a versatile PROTAC linker featuring a bromo group and an azide moiety, designed for the synthesis of antibody-drug conjugates (ADCs) and PROTACs. This compound functions effectively in click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, Bromo-PEG2-C2-azide can participate in strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN groups, making it a valuable tool for targeted protein degradation and bioconjugation strategies in chemical biology research. -
PROTAC Linker
Azido-PEG4-C2-acid is a PEG-based linker designed for use in PROTAC (Proteolysis Targeting Chimeras) applications. It serves as a non-cleavable linker in the synthesis of antibody-drug conjugates (ADCs) and is integral to the development of compounds such as vRucaparib-TP4. This compound features an azide group that enables the copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with alkyne-containing molecules, and it also facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN groups, making it a versatile reagent for chemical biology research. -
ADC/PROTAC Linker
Bis-PEG9-NHS ester is a polyethylene glycol (PEG)-based linker designed for use in antibody-drug conjugates (ADCs) and PROTACs (proteolysis-targeting chimeras). This cleavable linker facilitates the attachment of drugs to antibodies, enhancing selective delivery and activity. Its application in PROTAC synthesis allows for targeted protein degradation, making it a valuable tool in drug discovery and development. -
PROTAC Linker
N3-PEG3-CH2CH2COOH is a PEG-based PROTAC linker that facilitates selective protein degradation by enabling the synthesis of specific PROTACs, including BI-3663 and BI-4216. This compound contains an azide group, allowing it to engage in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne, DBCO, or BCN-containing molecules. N3-PEG3-CH2CH2COOH is also applicable as a non-cleavable ADC linker in the development of antibody-drug conjugates, making it a versatile reagent for chemical biology research. -
ADC/PROTAC Linker
N-Boc-PEG1-bromide is a versatile cleavable linker targeting ADCs and PROTACs. This PEG/alkyl/ether-based reagent facilitates the synthesis of antibody-drug conjugates (ADCs) and enhances the design of proteolysis-targeting chimeras (PROTACs). Its unique properties allow for effective conjugation and release mechanisms, making it suitable for various applications in chemical biology and drug development research. -
ADC/PROTAC Linker
Bis-PEG5-NHS ester is a polyethylene glycol (PEG) based linker that targets protein degradation for the development of PROTACs (proteolysis targeting chimeras) and serves as a cleavable linker in antibody-drug conjugates (ADCs). This compound facilitates the conjugation of bioactive molecules with antibodies, enhancing the targeted delivery of therapeutic agents. Its versatile application in synthesizing both PROTACs and ADCs makes it valuable for advancing research in targeted therapies and drug delivery systems. -
PROTAC Linker
Amino-PEG4-alcohol is a PEG-based linker designed for use in the synthesis of PROTACs (Proteolysis Targeting Chimeras). This linker facilitates the assembly of heterobifunctional molecules and enables targeted degradation of proteins within cellular systems. Additionally, Amino-PEG4-alcohol serves as a non-cleavable 4-unit PEG linker for the development of antibody-drug conjugates (ADCs), enhancing the delivery of therapeutic agents. It is suitable for applications in chemical biology and drug development research. -
ADC/PROTAC Linker
Azido-PEG7-amine is a non-cleavable 7-unit polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs) and PROTACs (Proteolysis Targeting Chimeras). This versatile linker features an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups. Azido-PEG7-amine serves as an important tool for the development of advanced bioconjugates in chemical research. -
PROTAC Linker
Boc-NH-PEG4-CH2CH2COOH is a PEG-based linker designed for use in the synthesis of PROTACs (Proteolysis Targeting Chimeras), facilitating targeted degradation of specific proteins. Additionally, this compound serves as a cleavable linker for antibody-drug conjugates (ADCs), enhancing the delivery of therapeutic agents to specific cellular targets. Its versatile applications make it a valuable tool in chemical biology and drug development research. -
ADC/PROTAC Linker
N-Boc-PEG4-bromide is a PEG-based linker that functions as a cleavable agent in antibody-drug conjugates (ADCs) and PROTACs. This compound facilitates the synthesis of PROTACs by providing a flexible and hydrophilic connector, enhancing solubility and biological activity. Its functional bromide group allows for effective conjugation to various biomolecules, making it a valuable tool in drug development research. -
PROTAC Linkers
Azido-PEG5-alcohol functions as a non-cleavable linker in the synthesis of antibody-drug conjugates (ADCs) and as a versatile PEG-based linker for PROTAC (proteolysis-targeting chimeras) development. It is characterized by its azide group, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) with alkyne, DBCO, or BCN-functionalized molecules. This reagent is instrumental in creating stable linkages for targeted protein degradation and therapeutic antibody conjugation, enhancing the efficacy of research applications in drug development. -
PROTAC Linkers
Azido-PEG6-amine is a PEG-based PROTAC linker featuring an azide functional group, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) with alkyne-bearing and DBCO or BCN-containing molecules. This compound plays a crucial role in the synthesis of PROTACs, facilitating targeted protein degradation. Additionally, it serves as a non-cleavable linker in the development of antibody-drug conjugates (ADCs), providing significant versatility for researchers engaged in drug development and therapeutic applications. -
PROTAC Linker
Bis-PEG3-NHS ester is a non-cleavable linker that features a three-unit polyethylene glycol (PEG) structure, designed for use in the construction of PROTACs (proteolysis-targeting chimeras). This reagent facilitates the effective conjugation of antibodies to various agents, enhancing their therapeutic potential. Its unique properties make it suitable for applications in targeted drug delivery and protein degradation studies. -
Azide Compound
DBCO-PEG2-NHS ester is a click chemistry reagent with an azide group, designed to facilitate bioconjugation through reactions with primary amines, such as lysine side chains or aminosilane-coated surfaces. This PEG-based compound features an NHS ester, which enables the formation of stable covalent bonds under neutral to slightly basic conditions. The hydrophilic polyethylene glycol (PEG) spacer enhances solubility and adds flexibility, reducing steric hindrance during ligation. DBCO-PEG2-NHS ester is ideal for applications in copper-free Click Chemistry and other bioconjugation studies. -
ADC/PROTAC Linker
N-Boc-PEG2-bromide is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs) and PROTACs. Its PEG-based structure facilitates enhanced solubility and flexibility, contributing to improved therapeutic efficacy. This reagent is essential for researchers focused on developing targeted drug delivery systems and studying protein degradation pathways. -
PROTAC/ADC Linker
NH2-PEG2-C2-Boc is a PEG-based linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This non-cleavable linker comprises two PEG units, facilitating efficient conjugation while ensuring stability in biological systems. Its application is crucial in the development of targeted therapeutics, enabling precise modulation of protein degradation and enhancing the efficacy of ADCs in research and therapeutic contexts.
